#### EAGLE PHARMACEUTICALS, INC.

Form 4

February 20, 2014

# FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

**OMB APPROVAL** 

response...

burden hours per

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* ProQuest Associates IV LLC

2. Issuer Name and Ticker or Trading

Symbol

5. Relationship of Reporting Person(s) to Issuer

EAGLE PHARMACEUTICALS,

(Check all applicable)

INC. [EGRX]

(Month/Day/Year)

02/18/2014

(Last) (First) 3. Date of Earliest Transaction

Director Officer (give title below)

X\_\_ 10% Owner \_ Other (specify

2430 VANDERBILT BEACH ROAD, 108-190

> (Street) 4. If Amendment, Date Original

(Middle)

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person \_X\_ Form filed by More than One Reporting

Person

NAPLES, FL 34109

						Person						
(City) (State)			(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
	1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Appropriate Appr	f (D)	red (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
	Common Stock, \$0.001 par value	02/18/2014		C	1,927,986	A	(1)	1,966,987	I	By ProQuest Investments IV, L.P. (2)		
	Common Stock, \$0.001 par value	02/18/2014		С	1,028,616	A	(1)	2,995,600	I	By ProQuest Investments IV, L.P. (2)		
	Common Stock, \$0.001	02/18/2014		С	850,520	A	(1)	3,846,120	I	By ProQuest Investments IV, L.P. (2)		

#### Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 4

par value								
Common Stock, \$0.001 par value	02/18/2014	С	569,538	A	<u>(1)</u>	4,415,658	I	By ProQuest Investments IV, L.P. (2)
Common Stock, \$0.001 par value	02/18/2014	X	21,837	A	(3)	4,437,495	I	By ProQuest Investments IV, L.P. (2)
Common Stock, \$0.001 par value	02/18/2014	P	333,333	A	\$ 15	4,770,828	I	By ProQuest Investments IV, L.P. (2)
Common Stock, \$0.001 par value	02/18/2014	С	62,575	A	(1)	71,934	I	By ProQuest Management LLC Plans (4)
Common Stock, \$0.001 par value	02/18/2014	С	9,359	A	(1)	72,291	I	By ProQuest Management LLC Plans (4)
Common Stock, \$0.001 par value	02/18/2014	X	357	A	<u>(3)</u>	72,291	I	By ProQuest Management LLC Plans (4)
Common Stock, \$0.001 par value						9,360	I	By ProQuest Management LLC (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	Disposed	ve es d (A) or	6. Date Exerc Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares

### Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 4

Series A Convertible Preferred Stock	(1)	02/18/2014	С	1,927,986 (6)	<u>(1)</u>	<u>(7)</u>	Common Stock	1,927, (6)
Series B Convertible Preferred Stock	<u>(1)</u>	02/18/2014	С	1,028,613 (6)	<u>(1)</u>	<u>(7)</u>	Common Stock	1,028, (6)
Series B-1 Convertible Preferred Stock	<u>(1)</u>	02/18/2014	С	850,520 ( <u>6)</u>	<u>(1)</u>	<u>(7)</u>	Common Stock	850,5 (6)
Series C Convertible Preferred Stock	<u>(1)</u>	02/18/2014	С	569,538 (6)	<u>(1)</u>	<u>(7)</u>	Common Stock	569,5 (6)
Series C Warrants	(3)	02/18/2014	X	98,368 (3)	(3)	<u>(3)</u>	Common Stock	98,368
Series B-1 Convertible Preferred Stock	<u>(1)</u>	02/18/2014	С	62,575 <u>(6)</u>	<u>(1)</u>	<u>(7)</u>	Common Stock	62,575
Series C Convertible Preferred Stock	(1)	02/18/2014	С	9,359 (6)	<u>(1)</u>	<u>(7)</u>	Common Stock	9,359
Series C Warrants	(3)	02/18/2014	X	1,614 (3)	<u>(3)</u>	(3)	Common Stock	1,614

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
ProQuest Associates IV LLC 2430 VANDERBILT BEACH ROAD, 108-190 NAPLES, FL 34109		X					
ProQuest Investments IV, L.P. 2430 VANDERBILT BEACH ROAD, 108-190 NAPLES, FL 34109		X					
ProQuest Management LLC 2430 VANDERBILT BEACH ROAD, 108-190 NAPLES, FL 34109		X					

Reporting Owners 3

## **Signatures**

/s/ Scott Tarriff, Attorney-in-Fact 02/20/2014

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and (1) Series C Convertible Preferred stock automatically converted into one share of the Issuer's Common Stock on a 6.41-for-1 basis immediately prior to the consummation of the Issuer's initial public offering.
- The shares are owned by ProQuest Investments IV, of which ProQuest Associates IV LLC ("Associates IV") is the general partner. Jay (2) Moorin and Alain Schreiber are managing members of Associates IV. Each of the Reporting Persons disclaims beneficial ownership of such securities except to the extent of each Reporting Person's pecuniary interest in such securities
- (3) In accordance with their terms, the Series C Warrants (the "Warrants") were net exercised at an exercise price of \$11.67 immediately prior to the consummation of the Issuer's initial public offering into shares of Common Stock on a 6.41-for-1 basis.
  - The shares are held in a ProQuest Management LLC Defined Benefit Pension Plan ("DBPP") FBO Jay Moorin and a ProQuest Management LLC Salary Savings Plan FBO Jay Moorin and for the benefit of certain other individuals. Jay Moorin and Alain Schreiber
- (4) are trustees of ProQuest Management LLC DBPP FBO Jay Moorin and the ProQuest Management LLC Salary Savings Plan FBO Jay Moorin and for the benefit of certain other individuals. Each of the Reporting Persons disclaims beneficial ownership of such securities except to the extent of each Reporting Person's pecuniary interest in such securities.
- The shares are owned by ProQuest Management LLC (ProQuest Management"). Jay Moorin and Alain Schreiber are managing members of ProQuest Management. Each of the Reporting Persons disclaims beneficial ownership of such securities except to the extent of each Reporting Person's pecuniary interest in such securities.
- (6) Reflects a 1-for-6.41 reverse stock split, pursuant to which each share of preferred stock became convertible into 1/6.41 of a share of common stock.
- (7) The expiration date is not relevant to the conversion of these securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 4